Simon Haron, Ethan J Kilmister, Paul F Davis, Stanley S Stylli, Theo Mantamadiotis, Andrew H Kaye, Sean R Hall, Swee T Tan, Agadha C Wickremesekera
Despite their differences, central nervous system (CNS) tumors and degenerative diseases share important molecular mechanisms underlying their pathologies, due to their common anatomy. Here we review the role of the renin-angiotensin system (RAS) in CNS tumors and degenerative diseases, to highlight common molecular features and examine the potential merits in repurposing drugs that inhibit the RAS, its bypass loops, and converging signaling pathways. The RAS consists of key components, including angiotensinogen, (pro)renin receptor (PRR), angiotensin-converting enzyme 1 (ACE1), angiotensin-converting enzyme 2 (ACE2), angiotensin I (ATI), angiotensin II (ATII), ATII receptor 1 (AT1 R), ATII receptor 2 (AT2 R) and the Mas receptor (MasR)...
September 30, 2021: Frontiers in Bioscience (Landmark Edition)